)
)
Oculis Holding AG Investor Relations Material
Latest events
Study Result
Oculis Holding AG
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from Oculis Holding AG
Access all reports
Oculis Holding AG is a global biopharmaceutical company focused on developing innovative treatments for eye diseases. The company's product pipeline includes several advanced-stage candidates designed to address significant unmet needs in ophthalmology. Notable among these are OCS-01, a topical eye drop for diabetic macular edema and post-cataract surgery inflammation, OCS-02, a topical biologic targeting dry eye disease and uveitis, and OCS-05, aimed at neuro-ophthalmic conditions such as acute optic neuritis and glaucoma. The company is headquartered in Zug, Switzerland, and its shares are listed on the Nasdaq.
Key slides for Oculis Holding AG
Corporate Presentation
Oculis Holding AG
Corporate Presentation
Oculis Holding AG
Latest articles
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
)
Mips: The Gore-Tex of Brain Protection
How Mips turned a critical safety flaw into a global success, redefining helmet protection with its technology and ingredient brand business model.
24 Jan 2025
Ticker symbol
OCS
Country
🇺🇸 United States